Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesDividends payablesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Vycor Medical (VYCO) Common Equity (2016 - 2025)

Vycor Medical has reported Common Equity over the past 16 years, most recently at -$4.1 million for Q4 2025.

  • Quarterly Common Equity fell 10.75% to -$4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.1 million through Dec 2025, down 10.75% year-over-year, with the annual reading at -$4.1 million for FY2025, 10.75% down from the prior year.
  • Common Equity was -$4.1 million for Q4 2025 at Vycor Medical, down from -$4.0 million in the prior quarter.
  • Over five years, Common Equity peaked at $2.4 million in Q4 2021 and troughed at -$4.1 million in Q4 2025.
  • The 5-year median for Common Equity is -$3.2 million (2023), against an average of -$2.9 million.
  • Year-over-year, Common Equity surged 220.89% in 2021 and then tumbled 222.78% in 2022.
  • A 5-year view of Common Equity shows it stood at $2.4 million in 2021, then tumbled by 222.78% to -$2.9 million in 2022, then decreased by 13.08% to -$3.3 million in 2023, then dropped by 10.96% to -$3.7 million in 2024, then decreased by 10.75% to -$4.1 million in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Common Equity are -$4.1 million (Q4 2025), -$4.0 million (Q3 2025), and -$3.9 million (Q2 2025).